van Duijnhoven E et al. |
The effect of breakfast on the oral bioavailability of tacrolimus in diabetic and nondiabetic patients before transplantation. |
1998 |
Transplant. Proc. |
pmid:9636515
|
Christiaans M et al. |
Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. |
1998 |
Transplant. Proc. |
pmid:9636516
|
Sato S et al. |
Specificity of therapeutic drug monitoring of tacrolimus in kidney transplant patients. |
1998 |
Transplant. Proc. |
pmid:9636517
|
Uchida K et al. |
Decreasing pancreatic toxicity of tacrolimus by dosage reduction. |
1998 |
Transplant. Proc. |
pmid:9636518
|
Rostaing L et al. |
Early posttransplantation renal hemodynamics in FK 506-treated kidney recipients with or without prior induction therapy. |
1998 |
Transplant. Proc. |
pmid:9636519
|
Rostaing L et al. |
Influence of early FK 506 trough levels on glomerular hemodynamics at 3 months in kidney transplant recipients. |
1998 |
Transplant. Proc. |
pmid:9636520
|
Morris-Stiff G et al. |
Pharmaco-economic study of FK 506 (Prograf) and cyclosporine A Neoral in cadaveric renal transplantation. |
1998 |
Transplant. Proc. |
pmid:9636521
|
Mendez R |
FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. |
1998 |
Transplant. Proc. |
pmid:9636522
|
Vanrenterghem Y et al. |
Co-administration of tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. |
1998 |
Transplant. Proc. |
pmid:9636523
|
Claesson K et al. |
Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. |
1998 |
Transplant. Proc. |
pmid:9636524
|
Morris-Stiff G et al. |
Prospective randomized study comparing FK 506 (Prograft) and cyclosporine A (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. |
1998 |
Transplant. Proc. |
pmid:9636525
|
Woodle ES et al. |
Meta-analysis of FK 506 and mycophenolate mofetil refractory rejection trials in renal transplantation. Refractory Rejection Meta-Analysis Study Group. |
1998 |
Transplant. Proc. |
pmid:9636526
|
Undre NA et al. |
Pharmacokinetics of FK 506 and mycophenolic acid after the administration of a FK 506-based regimen in combination with mycophenolate mofetil in kidney transplantation. |
1998 |
Transplant. Proc. |
pmid:9636527
|
Kumar MS et al. |
ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. |
1998 |
Transplant. Proc. |
pmid:9636549
|
Neylan JF |
Effect of race and immunosuppression in renal transplantation: three-year survival results from a US multicenter, randomized trial. FK506 Kidney Transplant Study Group. |
1998 |
Transplant. Proc. |
pmid:9636551
|
Fitzsimmons WE et al. |
Demographic considerations in tacrolimus pharmacokinetics. |
1998 |
Transplant. Proc. |
pmid:9636552
|
Shapiro R et al. |
Outcome after steroid withdrawal in renal transplant patients receiving tacrolimus-based immunosuppression. |
1998 |
Transplant. Proc. |
pmid:9636557
|
Grewal HP et al. |
Corticosteroid cessation 1 week following renal transplantation using tacrolimus/mycophenolate mofetil based immunosuppression. |
1998 |
Transplant. Proc. |
pmid:9636558
|
Rossi G et al. |
Three-year follow-up of low dose tacrolimus oral therapy after liver transplantation: a single-centre experience. |
1998 |
Transplant. Proc. |
pmid:9636562
|
Samuel D et al. |
Tacrolimus (FK506)-based dual versus triple therapy following liver transplantation. |
1998 |
Transplant. Proc. |
pmid:9636563
|